Clinical Trial Update: Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC [NA]

View source ↗

Summary

A recruiting trial of Regorafenib and Sintilimab with electroacupuncture for microsatellite-stable metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)
• Sintilimab (Tyvyt) (sintilimab)

Snippet

Sponsor: The First People's Hospital of Changzhou | Conditions: Colorectal Cancer Metastatic | NA | Status: RECRUITING